Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Varivax (varicella live virus vaccine) by Year
Varivax (varicella live virus vaccine) — Worldwide sales ($M) ($M)
Merck Varivax (varicella live virus vaccine): $1,041M in FY2025, down 5.5% from a year earlier.
Where the FY2025 figure comes from
“|| Varivax | 1,041 | (6) | % | (6) | % | 1,102 | 3 | % | 4 | % | 1,068”
Source: Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K MD&A Pediatric Vaccines Disclosure (Q4 derived as Full Year − 9M).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Varivax (varicella live virus vaccine) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,041 | -5.5% | Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 1,102 | +3.2% | Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 1,068 | +7.8% | Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 991 | +2.1% | Form 10-K (mrk-20241231.htm, filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 971 | +18.0% | Form 10-K (mrk-20231231.htm, filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 823 | -15.2% | Form 10-K (mrk-20221231.htm, filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 970 | +25.3% | Form 10-K (mrk-20211231.htm, filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 774 | +0.9% | Form 10-K (mrk-20201231.htm, filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 767 | – | Form 10-K (mrk1231201910k.htm, filed 2020-02-26) ↗ |
Breakdown
What makes up varivax (varicella live virus vaccine)
Cite this data
StockData. (2026). Merck Varivax (varicella live virus vaccine) ($M), annual FY2017–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-varivax
See every metric in the Merck KPI table. Data updated Oct 26, 2026.